Glenmark and GBR401

by Savitha C Muppala on  April 1, 2011 at 8:30 PM Corporate News
RSS Email Print This Page Comment
The discovery and initiated IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR401 and anti-CD19 monoclonal antibody, has been announced by Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India.
 Glenmark and GBR401
Glenmark and GBR401
Advertisement

The brain-child of Glenmark's Biologics Research Centre, GBR 401 helps in targeting diseases like lymphomas and leukemia's of B-cell origin.

Advertisement


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive